Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future...

Area of Science:

• Oncology
• Translational Medicine
• Drug Development

Background:

• Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is aggressive with poor prognosis.
• Current systemic treatments offer limited clinical benefits for R/M HNSCC.
• There is an urgent need for improved therapeutic strategies.

Purpose of the Study:

• To review the biological principles and antigen targets of antibody-drug conjugates (ADCs).
• To summarize the current clinical development progress of ADCs in R/M HNSCC.
• To provide a comprehensive overview of preclinical and clinical evidence for ADC therapy in R/M HNSCC.

Main Methods:

• Systematic review of preclinical and clinical studies on ADCs for R/M HNSCC.
• Explanation of ADC structural principles and mechanisms of action.
• Analysis of antigen targets and clinical trial data.

Main Results:

• ADCs combine tumor-targeting antibodies with potent cytotoxic payloads for selective cancer cell delivery.
• Encouraging clinical signals have been observed in early and late-stage trials for R/M HNSCC.
• ADCs represent a highly promising therapeutic strategy for R/M HNSCC.

Conclusions:

• ADCs are an innovative and promising therapeutic approach for R/M HNSCC.
• Further translational research and clinical trials are ongoing.
• ADCs have the potential to significantly improve outcomes for patients with R/M HNSCC.